Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2013; 19(17): 2676-2682
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2676
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2676
Figure 1 Clinical remission rate.
Combinational therapy with adalimumab and azathioprine significantly increased the clinical remission rate vs nonconcomitant use at week 24.
- Citation: Ishida K, Inoue T, Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, Abe Y, Takeuchi T, Murano M, Tokioka S, Umegaki E, Higuchi K. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 2013; 19(17): 2676-2682
- URL: https://www.wjgnet.com/1007-9327/full/v19/i17/2676.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i17.2676